United States Department of Transportation
i
Gene Expression Biomarkers of the Response To Sleep Loss With and Without Modafinil [Supporting Datasets]
-
2023-10-20
-
[ZIP-44.42 MB]
Details:
-
Creators:
-
Corporate Creators:
-
Subject/TRT Terms:
-
Publication/ Report Number:
-
DOI:
-
Resource Type:
-
Geographical Coverage:
-
Corporate Publisher:
-
Abstract:Sleep disruption presents a substantial risk to health and safety, particularly due to the risks of performance degradation in safety-critical operations that can result in catastrophic injuries or mortality. Federal regulations exist to minimize the risks of fatigue with limitations on hours worked and requirements for fatigue risk management plans. Yet, even with workload controls and scheduled opportunities for rest, fatigue may be caused by factors such as personal and lifestyle choices, illness, and circadian disruption from travel across multiple time zones. Complicating risk mitigation is the challenge of identifying and measuring fatigue. Here, we report on gene expression biomarkers (biological indicators) for cognitive impairment during sleep loss. We observe hundreds of genes whose expression is associated with attention changes during one night of sleep loss. Several genes are identified that we previously associated with attention impairment in a separate study of sleep loss. The reproducibility of findings may indicate the robustness of these candidate fatigue impairment biomarkers. However, some biomarker genes only associate with certain tests of impairment (e.g., attention lapses but not self-reported fatigue), suggesting that different biomarker panels may be developed to assess the particular cognitive domains that need monitoring for a given safety critical operation. We also find that using a drug countermeasure (modafinil) not only helps mitigate impairment on tests of attention lapses, but also disrupts gene expression associations with attention lapses. Further research is needed to confirm whether this represents a unique effect of modafinil administration, or emphasizes the need to ensure biomarker validation occurs both in the presence and absence of countermeasures.
The total size of the zip file is 44.4 MB. The .txt file type is a common text file, which can be opened with a basic text editor. The most common software used to open .txt files are Microsoft Windows Notepad, Sublime Text, Atom, and TextEdit (for more information on .txt files and software, please visit https://www.file-extensions.org/txt-file-extension). The .xlsx and .xls file types are Microsoft Excel files, which can be opened with Excel, and other free available spreadsheet software, such as OpenRefine. The .csv, Comma Separated Value, file is a simple format that is designed for a database table and supported by many applications. The .csv file is often used for moving tabular data between two different computer programs, due to its open format. The most common software used to open .csv files are Microsoft Excel and RecordEditor, (for more information on .csv files and software, please visit https://www.file-extensions.org/csv-file-extension).
-
Content Notes:National Transportation Library (NTL) Curation Note: This dataset has been curated by the NTL Data Services Team. NTL staff last accessed this dataset on 2023-11-27. If, in the future, you have trouble accessing this dataset, please email NTLDataCurator@dot.gov describing your problem. NTL staff will do its best to assist you at that time.
-
Format:
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
